# BroadenBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/broadenbio-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.broadenbio.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 12, 2025)
- Investors on record: 4

## About

Based in Beijing, China and established in 2018, BroadenBio Co., Ltd. operates as a biopharmaceutical company that focuses on immuno-oncology and autoimmune diseases fields. Mr. Xingmin Zhang is the founder and CEO of the company. In December 2025, the company raised CNY 100 million in series A+ funding from E-Town International Industrial Investment, BCT Capital and Lapam Capital.

The company works with clinical research institutions and healthcare stakeholders to develop novel small-molecule therapeutics. Its pipeline includes BB102, a FGFR4 inhibitor in Phase II clinical trials for hepatocellular carcinoma, BB3008 in Phase Ib clinical development with immunomodulatory properties, and multiple preclinical candidates addressing oncology and autoimmune disease indications.

The company plans to advance its lead clinical programs, expand its preclinical pipeline and progress selected assets toward international clinical development and regulatory pathways.

## Funding rounds

- Series A, Dec 12, 2025, $14M — E-Town International Industrial Investment, Lapam Capital, BCT Capital
- Angel, Mar 1, 2020 — Zhongguancun Kaiyuan Capital
- Angel, Aug 23, 2018 — Lapam Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Angel, Series A
- Zhongguancun Kaiyuan Capital (https://capitalatlas.ai/funds/zhongguancun-kaiyuan-capital) — Angel
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series A
- BCT Capital (https://capitalatlas.ai/funds/bct-capital) — Series A